MedTrace Logo

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

NCT05343117 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2022-04-26

No results posted yet for this study

Summary

A multi-center non-interventional observational study led by the Cancer Hospital Chinese Academy of Medical Sciences to compare the effectiveness of palbociclib based-therapy as initial endocrine therapy versus palbociclib based-therapy after chemotherapy for HR+/HER2- advanced breast cancer.

Conditions

  • Hormone Receptor Positive Advanced Breast Cancer

Interventions

DRUG

Palbociclib based-therapy as initial endocrine therapy

Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)

DRUG

Palbociclib based-therapy after chemotherapy

Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Peng Yuan, M.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-12-31
Completion
2024-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05343117 on ClinicalTrials.gov